After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025'
March 19, 2025 10:08 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD)
The analyst comments "While recent reports (WSJ, Mar 18) suggest the Department of Health and Human Services may cut federal funding for HIV prevention, we believe... More
BTIG Reiterates Buy Rating on HealthEquity, Inc (HQY)
March 19, 2025 4:53 AM EDTBTIG analyst David Larsen reiterated a Buy rating and $130.00 price target on HealthEquity, Inc (NASDAQ: HQY).
The analyst comments "On Tuesday, 3/18/25 AMC, HQY reported F4Q:25 results. Total revenue of $311.8M +19% y/y was well ahead of BTIG / consensus estimates of $306.8M / $306M but adjusted EBITDA of $107.8M +9% y/y missed BTIG... More
